Is larotrectinib available in the country?

Larotrectinib is a targeted therapy drug that is part of the field of molecular targeted therapy. Its main role is to treat a specific type of tumor, namely TRK (neuronal growth factor receptor) gene fusion-positive tumors.

Larotrectinib has been launched in China, but it has not been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in China. Please consult the local hospital pharmacy for details. There are original drugs and generic drugs of larotrectinib abroad. The original drugs include German version, American version, European version and Hong Kong version. The price is basically around 20,000 yuan. Generic drugs include Lao and Bangladeshi versions, with prices ranging from two to three thousand. The ingredients of original drugs and generic drugs are basically the same.

Larotinib is a targeted therapy drug whose design and mechanism of action are specifically targeted at a specific molecular target, theTRK protein. TRKGene fusions are rare but widespread cancer-related genetic abnormalities that can be found in multiple cancer types. The mechanism of action of larotrectinib is to affect abnormal signaling by inhibiting the activity of TRK protein, thereby reducing the proliferation and survival of tumor cells. The design of this drug makes it highly specific, mainly targeting TRK gene fusion, so it can reduce the adverse effects on normal cells and reduce the toxic and side effects compared with traditional chemotherapy drugs.

The main indication of larotrectinib is the treatment of TRK gene fusion-positive tumors. This drug can be used for a variety of cancer types, including but not limited to childhood tumors, adult lung cancer, breast cancer, kidney cancer, colorectal cancer, and thyroid cancer.

The use of larotrectinib requires TRK gene fusion testing to determine whether there is TRK gene fusion. This personalized treatment approach ensures that drugs are used only in patients for whom they are indicated, reducing unnecessary treatment for other patients while providing more precise treatment.